Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer

Breast Neoplasms Clinical Trial

Official title:

Evaluation of Single Fraction High-Gradient Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-Risk Stage 0 and I Breast Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02076074
• Other study ID #: 201401160
• Status: Completed
• Phase: N/A
• Start date: April 2, 2014
• Est. completion date: May 18, 2023

Study information

• Verified date: November 2023
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II clinical trial studies the side effects of delivering radiation therapy in a single session instead of multiple treatments over several weeks and to see how well it works in treating patients with low-risk stage 0-I breast cancer. Partial-breast irradiation, a type of radiation therapy focused only to the part of the breast that has cancer in it, given at a lower dose than standard whole-breast radiation therapy. Single fraction high-gradient partial-breast irradiation may cause fewer side effects, help prevent breast cancer from coming back, and improve the appearance of the breast and quality of life of patients with breast cancer.

Description:

This is a phase I/II study which will evaluate the complication rates, local control, cosmetic results, and quality of life of single fraction high gradient partial breast irradiation (HG-PBI) when used as the sole method of radiation therapy for patients with pathologic stage 0 (=< 2 cm) or I carcinoma of the breast treated with partial mastectomy with histologically assessed negative surgical margins.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: May 18, 2023
• Est. primary completion date: May 18, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• AJCC 7th Edition stage 0 or I (TisN0 = 2 cm or T1N0) histologically confirmed carcinoma of the breast, treated with partial mastectomy. Axillary sampling is required only for cases of invasive cancers. Tumor size is determined by the pathologist. Clinical size may be used if the pathologic size is indeterminate. Patients with invasive cancer must have no positive axillary lymph nodes with at least 6 axillary lymph nodes sampled or a negative sentinel node.

• Negative histologic margins of partial mastectomy or re-excision specimen. Margins generally are positive if there is invasive or noninvasive tumor at the inked resection margin, close but negative if the tumor is within 2 mm of the inked margin and negative if the tumor is at least 2 mm away from the inked edge.

• Invasive ductal, lobular, medullary, papillary, colloid (mucinous), tubular histologies, or mixed histologies (lesions = 2 cm) that are estrogen or progesterone receptor positive and do not exhibit HER2/neu gene amplification OR ductal carcinoma in situ (lesions = 2 cm).

• Systemic therapy, if planned, must be adjuvant in nature and not be scheduled to begin for at least 4 weeks after completion of HG-PBI.

• Good candidate for treatment per protocol in the judgment of the PI and/or treating physician following simulation.

• Postmenopausal status.

• Age = 50 years at diagnosis.

• Able to understand and willing to sign IRB-approved written informed consent document.

• English speaker.

Exclusion Criteria:

• Presence of distant metastases.

• In situ lobular carcinoma or nonepithelial breast malignancies such as sarcoma or lymphoma.

• Proven multicentric carcinoma (tumors in different quadrants of the breast, or tumors separated by at least 4 cm) with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy.

• Premenopausal status.

• Histologically confirmed positive axillary nodes in the ipsilateral axilla. Palpable or radiographically suspicious contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor.

• Prior non-hormonal therapy for the present breast cancer, including radiation therapy or chemotherapy.

• Diagnosis of systemic lupus erythematosis, scleroderma, or dermatomyositis.

• Diagnosis of a coexisting medical condition which limits life expectancy to < 2 years.

• Diagnosis of psychiatric or addictive disorders that would preclude obtaining informed consent.

• History of other malignancy = 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.

• Paget's disease of the nipple.

• Skin involvement, regardless of tumor size.

• Unsatisfactory breast for HG-PBI as determined by the treating physician. For example, if there is little breast tissue remaining between the skin and pectoralis muscle after surgery, treatment with HG-PBI is technically problematic.

• Partial mastectomy so extensive that the cosmetic result is fair or poor prior to HG-PBI as determined by the treating physician.

• Surgical margins which cannot be microscopically assessed or are positive at pathological evaluation.

• Time between final definitive breast procedure to HG-PBI simulation is greater than 8 weeks.

Inclusion of Women and Minorities

-Women and members of all races and ethnic groups are eligible for this trial. Because breast cancer occurs rarely in men, men will not be recruited for participation.

Related Conditions & MeSH terms

• Breast Neoplasms

Intervention

Radiation:
• accelerated partial breast irradiation
Undergo HG-PBI

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients who are free of serious treatment related toxicity	Quantified by estimating the rate of acute and late treatment-related grade 3 or higher toxicity per CTCAE, version 4.0. Toxicities of concern include breast pain, delayed wound healing, persistent seroma fluid accumulation, breast fibrosis, and fat necrosis in the treated breast. Rare toxicities include radiation pneumonitis and pericarditis.	Up to 5 years
Primary	Proportion of patients who are free of breast cancer in the treated breast	Rate of patients without ipsilateral breast tumor recurrences (IBTR). Calculated with a 95% confidence interval.	At 5 years
Secondary	Proportion of patients who are free of breast cancer in the regional lymph nodes	Ipsilateral axilla, infraclavicular, supraclavicular, and internal mammary groups. Calculated with a 95% confidence interval.	At 5 years
Secondary	Proportion of patients who are free from distant metastases		At 5 years
Secondary	Change in quality of life as measured by the EORTC QLC-C30		Baseline, 2 weeks, 8 weeks, 6 months, 12 months, 18 months, 24 months, 36 months, year 4, and year 5
Secondary	Change in quality of life as measured by the QLQ-BR23		Baseline, 2 weeks, 8 weeks, 6 months, 12 months, 18 months, 24 months, 36 months, year 4, and year 5
Secondary	Change in quality of life as measured by the Visual Analog Scale for Pain		Baseline, 2 weeks, 8 weeks, 6 months, 12 months, 18 months, 24 months, 36 months, year 4, and year 5
Secondary	Cosmesis as measured by the Breast Retraction Assessment (BRA)	This instrument includes a formula expressing the extent of displacement of the treated breast relative to the contralateral breast and other anatomical features.	Baseline, 8 weeks, 6 months, 12 months, 24 months, 36 months, year 4, and year 5
Secondary	Cosmesis as measured by the percentage Breast Retraction Assessment (pBRA)	This instrument includes a formula expressing the extent of displacement of the treated breast relative to the contralateral breast and other anatomical features.	Baseline, 8 weeks, 6 months, 12 months, 24 months, 36 months, year 4, and year 5
Secondary	Cosmesis as measured by the Aronson modified Harris Scale.		Baseline, 8 weeks, 6 months, 12 months, 24 months, 36 months, year 4, and year 5
Secondary	Presence of complications using CTCAE v. 4.0		Up to 5 years
Secondary	Frequency of any grade 3-4 toxicities using CTCAE v4.0		Up to 5 years
Secondary	Proportion of patients undergoing mastectomy on the treated side		At 5 years

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine